Organization
Vall d'Hebron University Hospital
9 abstracts
2 posters
Abstract
3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR), Universidad Europea de Madrid,
Abstract
Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.Org: Dana-Farber Cancer Institute, Gustave Roussy Cancer Center, Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Memorial Sloan Kettering Cancer Center, Hospital Universitario 12 de Octubre,
Abstract
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.Org: Vall d’Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, The Ohio State University James Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University, University of Chicago,
Abstract
ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,
Abstract
Histopathological response (HR) after neoadjuvant chemotherapy (ChT) for high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 trial.Org: Department of Experimental Oncology, Milano, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Vall d'Hebron University Hospital, Bergonié Institute,
Abstract
Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.Org: Gustave Roussy Cancer Center, Université Paris Saclay, Paris, France, Royal Free London NHS Foundation Trust, UCL Division of Surgery and Interventional Science,
Abstract
Primary results from PATRICIA cohort C (SOLTI-1303), a randomized phase II study evaluating palbociclib with trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer.Org: SOLTI Cancer Research Group, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute, Vall d’Hebron Institute of Oncology,
Abstract
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.Org: GEICO, Arcagy-Gineco, NSGO-CTU, SAKK, BGOG,
Abstract
Comparing 18F-FDG positron emission tomography (PET) and breast magnetic resonance imaging (MRI) to predict pathological complete response (pCR) and 3-year invasive disease-free survival (3-y iDFS) in patients (pts) with HER2+ early breast cancer (EBC): An unplanned exploratory analysis of PHERGain trial.Org: International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Medica Scientia Innovation Research (MEDSIR) - Oncoclínicas&Co, Jersey City (New Jersey, USA),